Curative Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with ASXL1 Mutation.
10.19746/j.cnki.issn.1009-2137.2025.03.014
- Author:
Ya-Jie SHI
1
;
Xin-Sheng XIE
1
;
Zhong-Xing JIANG
1
;
Ding-Ming WAN
1
;
Rong GUO
1
;
Tao LI
1
;
Xia ZHANG
1
;
Xue LI
1
;
Yu-Pei ZHANG
1
;
Yue SU
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myeloid, Acute/therapy*;
Hematopoietic Stem Cell Transplantation;
Female;
Male;
Middle Aged;
Mutation;
Adult;
Repressor Proteins/genetics*;
Adolescent;
Retrospective Studies;
Aged;
Nucleophosmin;
Young Adult;
Transplantation, Homologous;
Prognosis;
Survival Rate
- From:
Journal of Experimental Hematology
2025;33(3):720-725
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the efficacy and apoptosis of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of acute myeloid leukemia (AML) with ASXL1 mutation.
METHODS:The clinical data of 80 AML patients with ASXL1 mutation treated in our hospital from January 2019 to December 2021 were retrospectively analyzed. The clinical characteristics of the patients were summarized, and the therapeutic effect and prognostic factors of allo-HSCT for the patients were analyzed.
RESULTS:Among the 80 patients, 38 were males and 42 were females, and the median age was 39(14-65) years. There were 17 patients in low-risk group, 25 patients in medium-risk group and 38 patients in high-risk group. ASXL1 mutation co-occurred with many other gene mutations, and the frequent mutated genes were TET2 (71.25%), NRAS (18.75%), DNMT3A (16.25%), NPM1 (15.00%), CEBPA (13.75%). Among medium and high-risk patients, 29 underwent allo-HSCT, while 34 received chemotherapy. The 2-year overall survival (OS) rate and disease-free survival (DFS) rate of the allo-HSCT group were 72.4% and 70.2%, while those of the chemotherapy group were 44.1% and 34.0%, respectively. The statistical analysis showed significant differences between the two groups (both P < 0.01). Multivariate analysis showed that age at transplantation >50- years and occurrence of acute graft-versus-host disease after transplantation were poor prognostic factors for OS and DFS in transplantation patients.
CONCLUSION:Allo-HSCT can improve the prognosis of AML patients with ASXL1 mutation.
